BEIJING, Dec 31 — China announced on Thursday that it had granted conditional marketing authorisation for its first self-developed COVID-19 vaccine, reports Xinhua news agency.
The inactivated vaccine, which got the approval from the National Medical Products Administration (NMPA), is developed by the Beijing Biological Products Institute Co Ltd under the China National Biotec Group (CNBG), which is affiliated with Sinopharm.
The interim results of its phase-3 clinical trials show 79.34 per cent efficacy against COVID-19, meeting the standards of the World Health Organisation and the NMPA, according to a press conference by the State Council joint prevention and control mechanism against COVID-19.
